FDA
-
-
-
-
-
-
-
uniQure BV (QURE) PT Raised to $71 at Stifel
-
-
-
-
-
-
-
uniQure plans UK regulatory filing for Huntington's disease gene therapy
-
-
-
-
-
-
-
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
-
-
-
-
-
-
-
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors
-
-
-
-
-
-
-
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors
-
-
-
-
-
-
-
Wells Fargo Downgrades uniQure BV (QURE) to Equal Weight
-
-
-
-
-
-
-
Stifel Reiterates Buy Rating on uniQure BV (QURE)
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

